• HCN4 Channels Couple Temperature to Heart Rate

  2026-10-05

  A 2023 bioRxiv preprint identifies a conserved M407/Y409 motif in HCN4 as a key determinant of heat-dependent pacemaker-current and heart-rate responses. By connecting channel mutagenesis with sinoatrial-node cells, isolated hearts, and mouse models, the study proposes a mechanistic link between temperature sensing and cardiac excitability while remaining limited by its preprint status and model-specific evidence.

• C34 TLR4 Inhibitor: Evidence, Context and Limits

  2026-10-05

  An evidence-focused overview of C34 as a TLR4 inhibitor, covering its reported selectivity, research relevance in macrophages, enterocytes and neuroinflammation, comparison with Taxus chinensis findings, and key limitations in translating supplier-level claims into validated biology.

• Phosphatase Inhibitor Cocktail and Signal Fidelity

  2026-10-04

  Phosphatase Inhibitor Cocktail K1015 supports protein phosphorylation preservation across analytical workflows. This article examines how phosphatase control can strengthen interpretation of AMPK-linked liver injury research while clarifying evidence limits and assay context.

• 8-Chloroadenosine: A Causal Lens on RNA Stability

  2026-10-03

  Explore how 8-Chloroadenosine can support a more rigorous RNA metabolism study by separating RNA synthesis effects from transcript decay. This article connects the reagent’s catalog profile with the RP3-340N1.2–IL-6 axis in NSCLC while emphasizing evidence strength, interpretation, and experimental boundaries.

• Wnt Agonist 1 (BML-284): Mechanism & Uses

  2026-10-02

  Wnt agonist 1, also called BML-284, is a small-molecule activator of canonical β-catenin/TCF signaling with a reported EC50 of approximately 0.7 μM. It supports pathway activation, cellular differentiation studies, developmental biology research, and carefully controlled tests of Wnt-linked chemoresistance mechanisms.

• FH1: Designing Better iHep Maturation Assays

  2026-10-01

  FH1 small molecule supports more functional iPS-derived hepatocyte-like cells through coordinated albumin, AFP, CYP3A4, and morphology readouts. This article presents an assay-design framework that connects hepatocyte maturation with emerging light-controlled gene regulation while clearly separating established evidence from future applications.

• (-)-Blebbistatin in Mechanogenomic Force Assays

  2026-10-01

  (-)-Blebbistatin is a selective non-muscle myosin II inhibitor for dissecting how actomyosin tension controls chromatin and gene expression. This guide translates force-mode mechanobiology into practical assay design, controls, and interpretation.

• Clarithromycin CYP3A Inhibitor Workflows

  2026-09-30

  Build reproducible CYP3A inhibition assays with Clarithromycin for statin metabolism interaction, pharmacokinetic studies, and broader drug-drug interaction research. This guide pairs practical solubilization and workflow controls with a CYP3A-independent comparator concept derived from the dabigatran reference study.

• Vemurafenib (PLX4032) in Melanoma Research

  2026-09-30

  Build genotype-aware melanoma assays with Vemurafenib (PLX4032), from short-term MAPK pathway measurements to resistance modeling and xenograft studies. This workflow emphasizes solvent control, matched BRAF backgrounds, early signaling kinetics, and ARID1A-linked resistance biology.

• Trichostatin A (TSA): HDAC Workflow Guide

  2026-09-29

  Trichostatin A (TSA) provides reversible HDAC inhibition for probing histone acetylation, cell-cycle control, differentiation, and cancer-cell responses. This guide translates TSA into practical dose-response, viability, and oncolytic-virus combination workflows while emphasizing controls, solvent management, and assay-specific optimization.

• Sulfamonomethoxine in Aquatic Research

  2026-09-29

  Sulfamonomethoxine, or SMM, requires different interpretation in antibacterial, antiprotozoal, and environmental assays. This evidence-based guide connects DHPS inhibition, the Azumiobodo hoyamushi study, formulation constraints, and aquatic risk assessment to improve experimental decisions.

• Toremifene in Breast Cancer: 20 Years of Evidence

  2026-09-28

  This review evaluates two decades of clinical and pharmacologic evidence for toremifene, a selective estrogen receptor modulator used in hormone-sensitive breast cancer. Its central contribution is to place toremifene alongside tamoxifen and aromatase inhibitors while examining efficacy, safety, metabolism, CYP2D6, and patient-specific endocrine treatment decisions.

• Stress Fiber Anisotropy and Force-Mode Gene Control

  2026-09-28

  Wei and colleagues used three-dimensional magnetic twisting cytometry to compare how force direction affects cell stiffness, chromatin deformation, and DHFR transcription. Their results identify stress-fiber anisotropy as a mechanical factor that helps explain why force modes can produce different cellular responses, while also showing that stiffness alone does not predict the transcriptional outcome.

• Oteseconazole (VT-1161): Assay Workflows & DDI Context

  2026-09-27

  A practical guide to using Oteseconazole (VT-1161) in Candida susceptibility studies, from stock preparation to MIC interpretation. It also explains why antifungal potency and drug-interaction screening belong in separate, complementary assay tracks.

• Escitalopram Workflows for Anxiety and SERT Research

  2026-09-26

  Build serotonin-transporter experiments around Escitalopram’s nanomolar activity while keeping assay context and vehicle controls explicit. A clinical moderator analysis offers a useful lesson for anxiolytic activity studies: measure anxiety-related outcomes separately rather than assuming they track depression endpoints.

8109 records 1/541 page Next 12345 下5页 Last page